Bertilimumab: Difference between revisions
Knowledgejwl (talk | contribs) Changed "binds to CAT-213" to "binds to eotaxin 1". Added Cambridge Antibody Technology reference, iCo therapeutics |
Knowledgejwl (talk | contribs) Added iCo Therapeutic company information and clinical trial news |
||
| Line 30: | Line 30: | ||
It was discovered by [[Cambridge Antibody Technology]] using their [[phage display]] technology<ref>http://jpet.aspetjournals.org/cgi/content/abstract/319/3/1395</ref>. Named CAT-213 during early discovery and development by CAT, it was to be used to treat sever allergic disorders<ref>http://www.ncbi.nlm.nih.gov/pubmed/15573873</ref>. |
It was discovered by [[Cambridge Antibody Technology]] using their [[phage display]] technology<ref>http://jpet.aspetjournals.org/cgi/content/abstract/319/3/1395</ref>. Named CAT-213 during early discovery and development by CAT, it was to be used to treat sever allergic disorders<ref>http://www.ncbi.nlm.nih.gov/pubmed/15573873</ref>. |
||
In January 2007, CAT licensed the drug for treatment |
In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc. <ref>http://www.icotherapeutics.com/site/investor-relations/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/</ref>. iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'<ref>http://www.icotherapeutics.com/site/corporate_overview/overview/</ref>. |
||
iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008, and plan to initiate a Phase II clinical trial in patients with vernal [[keratoconjunctivitis]]<ref>http://www.icotherapeutics.com/site/pipeline/ico008/</ref>. |
|||
In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by [[Lonza Group|Lonza]], in its cGMP facilities in [[Slough]], [[UK]]. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield. iCo Therapeutics also announced that Dr. [[Santa J Ono]], iCo’s Chief Scientific Officer, is leading the comapny's drug programmes which include iCO-008. Furthermore Dr. Andrea Leonardi, Assistant Professor of Ophthalmology in the Department of Neuroscience, University of Padua is also involved<ref>http://www.icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_008_phase_ii_clinical_update/</ref>. |
|||
==References== |
|||
{{reflist}} |
|||
{{monoclonal-antibody-stub}} |
{{monoclonal-antibody-stub}} |
||
Revision as of 15:42, 1 August 2009
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | eotaxin-1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
Bertilimumab is a human monoclonal antibody that binds to eotaxin 1.
It was discovered by Cambridge Antibody Technology using their phage display technology[1]. Named CAT-213 during early discovery and development by CAT, it was to be used to treat sever allergic disorders[2].
In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc. [3]. iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'[4].
iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008, and plan to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis[5].
In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza, in its cGMP facilities in Slough, UK. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield. iCo Therapeutics also announced that Dr. Santa J Ono, iCo’s Chief Scientific Officer, is leading the comapny's drug programmes which include iCO-008. Furthermore Dr. Andrea Leonardi, Assistant Professor of Ophthalmology in the Department of Neuroscience, University of Padua is also involved[6].
References
- ^ http://jpet.aspetjournals.org/cgi/content/abstract/319/3/1395
- ^ http://www.ncbi.nlm.nih.gov/pubmed/15573873
- ^ http://www.icotherapeutics.com/site/investor-relations/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/
- ^ http://www.icotherapeutics.com/site/corporate_overview/overview/
- ^ http://www.icotherapeutics.com/site/pipeline/ico008/
- ^ http://www.icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_008_phase_ii_clinical_update/
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |